The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000;342:1 8. S8.1.2-56. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S8.1.2-57. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce athero- sclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1 45. S8.1.2-58. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pres- sure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2305 14. S8.1.2-59. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 97. S8.1.2-60. Julius S, Kaciroti N, Egan BM, et al. TROPHY study: outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2:39 43. S8.1.2-61. Luders S, Schrader J, Berger J, et al. The PHARAO study: pre- vention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487 96. S8.1.2-62. Fuchs SC, Poli-de-Figueiredo CE, Figueiredo Neto JA, et al. Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the PREVER Prevention Randomized Clinical Trial. J Am Heart Assoc. 2016;5:e004248. S8.1.2-63. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. 